Olink Holding AB (publ) Competitors

GoodRx (NASDAQ:GDRX) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for GoodRx and Olink Holding AB (publ), as provided by MarketBeat.com.

GoodRx currently has a consensus price target of $51.50, suggesting a potential upside of 63.75%. Olink Holding AB (publ) has a consensus price target of $44.00, suggesting a potential upside of 64.61%. Given Olink Holding AB (publ)'s stronger consensus rating and higher probable upside, analysts clearly believe Olink Holding AB (publ) is more favorable than GoodRx.

Profitability

This table compares GoodRx and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Institutional & Insider Ownership

43.4% of GoodRx shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares GoodRx and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

GoodRx has higher revenue and earnings than Olink Holding AB (publ).

Summary

GoodRx beats Olink Holding AB (publ) on 3 of the 5 factors compared between the two stocks.

Guardant Health (NASDAQ:GH) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Guardant Health and Olink Holding AB (publ), as provided by MarketBeat.com.

Guardant Health currently has a consensus price target of $170.50, suggesting a potential upside of 40.01%. Olink Holding AB (publ) has a consensus price target of $44.00, suggesting a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts clearly believe Olink Holding AB (publ) is more favorable than Guardant Health.

Profitability

This table compares Guardant Health and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Institutional & Insider Ownership

84.9% of Guardant Health shares are held by institutional investors. 13.0% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Guardant Health and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Olink Holding AB (publ) has lower revenue, but higher earnings than Guardant Health.

Summary

Guardant Health beats Olink Holding AB (publ) on 5 of the 9 factors compared between the two stocks.

ICON Public (NASDAQ:ICLR) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Earnings and Valuation

This table compares ICON Public and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

ICON Public has higher revenue and earnings than Olink Holding AB (publ).

Institutional & Insider Ownership

81.7% of ICON Public shares are held by institutional investors. 44.0% of ICON Public shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares ICON Public and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for ICON Public and Olink Holding AB (publ), as provided by MarketBeat.com.

ICON Public currently has a consensus price target of $236.00, suggesting a potential upside of 4.71%. Olink Holding AB (publ) has a consensus price target of $44.00, suggesting a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts clearly believe Olink Holding AB (publ) is more favorable than ICON Public.

Summary

ICON Public beats Olink Holding AB (publ) on 8 of the 9 factors compared between the two stocks.

Dr. Reddy's Laboratories (NYSE:RDY) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Valuation and Earnings

This table compares Dr. Reddy's Laboratories and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Dr. Reddy's Laboratories has higher revenue and earnings than Olink Holding AB (publ).

Institutional and Insider Ownership

12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Dr. Reddy's Laboratories and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dr. Reddy's Laboratories and Olink Holding AB (publ), as provided by MarketBeat.

Dr. Reddy's Laboratories presently has a consensus price target of $70.00, indicating a potential downside of 3.05%. Olink Holding AB (publ) has a consensus price target of $44.00, indicating a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts plainly believe Olink Holding AB (publ) is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats Olink Holding AB (publ) on 8 of the 9 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Olink Holding AB (publ) (NASDAQ:OLK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Masimo and Olink Holding AB (publ), as provided by MarketBeat.

Masimo presently has a consensus price target of $291.50, indicating a potential upside of 34.41%. Olink Holding AB (publ) has a consensus price target of $44.00, indicating a potential upside of 64.61%. Given Olink Holding AB (publ)'s higher probable upside, analysts plainly believe Olink Holding AB (publ) is more favorable than Masimo.

Valuation and Earnings

This table compares Masimo and Olink Holding AB (publ)'s top-line revenue, earnings per share and valuation.

Masimo has higher revenue and earnings than Olink Holding AB (publ).

Institutional and Insider Ownership

81.6% of Masimo shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Masimo and Olink Holding AB (publ)'s net margins, return on equity and return on assets.

Summary

Masimo beats Olink Holding AB (publ) on 8 of the 9 factors compared between the two stocks.

Olink Holding AB (publ) (NASDAQ:OLK) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Olink Holding AB (publ) and Novavax, as reported by MarketBeat.com.

Olink Holding AB (publ) presently has a consensus target price of $44.00, indicating a potential upside of 64.61%. Novavax has a consensus target price of $229.6429, indicating a potential upside of 43.08%. Given Olink Holding AB (publ)'s higher probable upside, equities research analysts clearly believe Olink Holding AB (publ) is more favorable than Novavax.

Valuation & Earnings

This table compares Olink Holding AB (publ) and Novavax's top-line revenue, earnings per share (EPS) and valuation.

Olink Holding AB (publ) has higher earnings, but lower revenue than Novavax.

Institutional & Insider Ownership

49.9% of Novavax shares are owned by institutional investors. 3.3% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Olink Holding AB (publ) and Novavax's net margins, return on equity and return on assets.

Summary

Novavax beats Olink Holding AB (publ) on 5 of the 9 factors compared between the two stocks.